A narrative review: research progress of adjuvant intensive endocrine therapy for early breast cancer
{{output}}
Background and objective: Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC) is the most prevalent subtype of all BCs. The primary treatment modality is endocrine therapy (E... ...
